Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.

[1]  Bong Su Kim,et al.  National surveillance of antifungal susceptibility of Candida species in South Korean hospitals. , 2009, Medical mycology.

[2]  I. Odeyemi,et al.  Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany , 2008, Current medical research and opinion.

[3]  A. Gorelik,et al.  A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients , 2006, Bone Marrow Transplantation.

[4]  S. Park,et al.  Current Trends of Infectious Complications following Hematopoietic Stem Cell Transplantation in a Single Center , 2006, Journal of Korean medical science.

[5]  T. Morimoto,et al.  Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy. , 2006, European journal of cancer care.

[6]  L. Annemans,et al.  Economic Evaluation of Intravenous Itraconazole for Presumed Systemic Fungal Infections in Neutropenic Patients in Korea , 2005, International Journal of Hematology.

[7]  J. Lipton,et al.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  S. Park,et al.  Cost-Identification Analysis between Amphotericin B deoxycholate and Intravenous Itraconazole in the Empirical Treatment of Febrile Neutropenic Patients:Preliminary Report , 2004 .

[9]  S. Lee,et al.  Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea , 2004, Bone Marrow Transplantation.

[10]  M. Ghannoum,et al.  Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients , 2004, Bone Marrow Transplantation.

[11]  J. Wingard,et al.  Infections following hematopoietic stem cell transplantation. , 2001, Infectious disease clinics of North America.

[12]  Victor R. Preedy,et al.  Korea National Statistical Office , 2010 .

[13]  L. Scott,et al.  Micafungin , 2012, Drugs.

[14]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Mark A. Wynne,et al.  The consumer price index , 1994 .